下载掌阅APP，畅读海量书库
立即打开
［1］HORYNOVA M S, VRABLIKOVA A, TYLER J, et al. N-Acetylgalactosaminide α2, 6-sialyltransferase Ⅱis a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy [J]. Nephrol Dial Transplant, 2015, 30 (2): 234-238.
［2］OKA K, NISHIMURA K, KISHIKAWA H, et al. IgA1 dominant subclass of latent IgA mesangial deposition in donated kidney [J]. Int J Nephrol Renovas Dis, 2016, 9: 313-317.
［3］SUN Y, LIU Z H, LIU Y, et al. Increased frequencies of memory and activated B cells and follicular helper T cells are positively associated with high levels of activation induced cytidine deaminase in patients with immunoglobulin A nephropathy [J]. Mol Med Rep, 2015, 12 (4): 5531-5537.
［4］ROPS A L, JANSEN E, SCHAAF A V, et al. Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice [J]. Kidney Int, 2018, 93 (6): 1356-1366.
［5］JIN L W, YE H Y, XU X Y, et al. MiR-133a/133b inhibits Treg differentiation in IgA nephropathy through targeting FOXP3 [J]. Biomed Pharmacother, 2018, 101: 195-200.
［6］JIANG M J, XIAOYUN X J, RONG L P, et al. Serum galactose-deficient IgA1 levels in children with IgA nephropathy [J]. Int J Clin Exp Med, 2015, 8 (5): 7861-7866.
［7］SUZUKI Y, MATSUZAKI K, SUZUKI H, et al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy [J]. Clin Exp Nephrol,2014, 18 (5): 770-777.
［8］MIZERSKA W M, GAJEWSKI U, CICHON K K, et al. Serum GDIgA1 levels in children with IgA nephropathy and Henoch-Schönlein nephritis [J]. Centr Eur Immunol, 2018, 43 (2): 162-167.
［9］KOSZTYU P, HILL M, JEMELKOVA J, et al. Glucocorticoids reduce aberrant O-glycosylation of IgA1 in IgA nephropathy patients [J]. Kidney Blood Press Res, 2018, 43 (2): 350-359.
［10］KIHARA M, ITO K, NAKATA J, et al. O-linked glycosylation determines the nephritogenic potential of IgA rheumatoid factor [J]. J Am Soc Nephrol, 2014, 25 (6): 1282-1290.
［11］LIANG Y, ZHANG J J, ZHOU Y L, et al. Proliferation and cytokine production of human mesangial cells stimulated by secretory IgA isolated from patients with IgA nephropathy [J]. Cell Physiol Biochem, 2015, 36 (5): 1793-1808.
［12］LIANG Y, ZHAO G Q, TANG L, et al. MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1β in mesangial cells activated by secretory IgA from IgA nephropathy patients [J]. Exp Cell Res, 2016, 347 (2): 312-321.
［13］BERTHELOT L, ROBERT T, VUIBLET V, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes [J]. Kidney Int, 2015, 88 (4): 815-822.
［14］POSGAI M T, TONDDAST N S, JAYASINGHE M, et al. FcαRI binding at the IgA1 C H 2-C H 3 interface induces long-range conformational changes that are transmitted to the hinge region [J]. Proc Natl Acad Sci USA, 2018, 115 (38): E8882-E8891.
［15］MOLYNEUX K, WIMBURY D, PAWLUCZYK I, et al. 1, 4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cells [J]. Kidney Int, 2017, 92 (6): 1458-1468.
［16］LOMAX H J, VISCONTI A, PUSEY C D, et al. IgA1 Glycosylation is heritable in healthy twins [J]. J Am Soc Nephrol, 2017, 28 (1): 64-68.
［17］LI C M, SHI J, ZHAO Y. MiR-320 promotes B cell proliferation and the production of aberrant glycosylated IgA1 in IgA nephropathy [J]. J Cell Biochem, 2018, 119 (6): 4607-4614.
［18］ZHAI YL, ZHU L, SHI SF, et al. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy [J]. Medicine, 2016, 95 (11): e3099.
［19］QI Y Y, ZHOU X J, CHENG F J, et al. Elevated plasma α -defensins (HNP1-3) levels correlated with IgA1 glycosylation and susceptibility to IgA nephropathy [J]. Dis Markers, 2016: 8123138.
［20］XIAO J, WANG M T, XIONG D W, et al. TGF-β1 mimics the effect of IL-4 on the glycosylation of IgA1 by downregulating core 1 β1, 3-galactosyltransferase and cosmc [J]. Mol Med Rep, 2017, 15 (2): 969-974.
［21］LIN J R, WEN J, ZHANG H, et al. Interleukin-17 promotes the production of underglycosylated IgA1 in DAKIKI cells [J]. Renal Fail, 2018, 40 (1): 60-67.
［22］YAMADA K, HUANG Z Q, RASKA M, et al. Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy [J]. Kidney Int Rep, 2017, 2 (6): 1194-1207.
［23］ZENG J W, MI R J, WANG Y C, et al. Promoters of human cosmc and T-synthase genes are similar in structure, yet different in epigenetic regulation [J]. J Bio Chem, 2015, 290 (31): 19018-19033.
［24］EBEFORS K, LIU P D, LASSEN E, et al. Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1 [J]. BMC Nephrology, 2016, 17: 40.
［25］NOVAK J, KAFKOVA L R, SUZUKI H, et al. IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells [J]. Nephrol Dial Transplant, 2011, 26 (11): 3451-3457.
［26］ZHAO Y F, ZHU L, LIU L J, et al. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy [J]. BMC Nephrology, 2017, 18 (1): 301.